|
2.13 ETIOLOGIE - NDMA
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
Designer antibodies fight cancer by tethering immune cells to tumor cells [Science]
|
|
|
|
|
|
Those new players in immunotherapy are no panacea yet. For some blood cancers, the bispecific antibodies aren’t giving patients the long-lasting remissions often seen with CAR T cells. As happened with CAR T cells, several patients have died in trials testing bispecific antibodies, possibly from overzealous immune responses sparked by the drugs.
|
|
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.5.1 ASCO (GÉNÉRAL)
|
|
|
|
|
5.5.10 ASCO (HÉMATO)
|
|
|
|
5.5.14 ASCO (VESSIE ET VOIES URINAIRES)
|
|
|
|
5.5.16 ASCO (MÉDECINE DE PRÉCISION)
|
|
|
|
5.5.18 ASCO (OBSERVATION)
|
|
|
|
|
5.5.19 ASCO (REIN)
|
|
|
|
5.5.4 ASCO (IMMUNOTHÉRAPIES)
|
|
|
|
5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)
|
|
|
|
|
|
5.5.7 ASCO (GYNÉCO)
|
|
|
|
|
5.5.8 ASCO (POUMON)
|
|
|
|
5.5.8 ASCO (POUMON) - OSIMERTINIB
|
|
|
|
|
|
|
|